Northern Ireland could lose half its veterinary medicines

Northern Ireland could lose half its veterinary medicines in Brexit row

Half of the veterinary medicines currently used in Northern Ireland could be withdrawn from sale unless there is a new deal with the EU, an inquiry has heard.

Human medicines were covered by the Windsor Framework, the revised Brexit deal for Northern Ireland.

That should guarantee the flow of those medicines from GB to NI.

But veterinary medicines were not part of the deal and are instead covered by a grace period which expires in 2026.

The House of Lords Windsor Framework Sub-Committee has begun an inquiry into the supply of veterinary medicines.

Industry representatives told it they want a deal similar to the one covering human medicines.

EU moves to end fears over animal medicine supplies
MPs concerned over NI animal medicine supplies
A simple guide to the Northern Ireland Brexit deal
Medicines have been one of the most difficult post-Brexit trade issues in Northern Ireland.

That is because Northern Ireland has remained in the EU's single market for goods, a market which includes medicines.

However, Northern Ireland gets most of its medicines from distributors and manufacturers in Great Britain.

Under the terms of the original deal, the Northern Ireland Protocol, medicines being sent from GB to NI would have required retesting and relabelling to ensure they met EU standards.

The pharmaceutical industry warned that would be an unviable expense for a market as small as NI, and medicines would be withdrawn from sale.

The EU ultimately agreed to major changes including the use of a single medicines pack for the whole of the UK, including Northern Ireland.

Not 'unresolvable'
However veterinary medicines still face the prospect of needing to meet those retesting and relabelling requirements, and the risk they will be withdrawn from sale as a consequence.

Head of regulatory affairs at the National Office of Animal Health, Donal Murphy, told the Lords committee a major reason veterinary medicines were not included in the deal was EU concerns about the food chain.

He said the European Commission assumed there would be further EU/UK divergence, which meant a risk veterinary medicines, which no longer aligned with EU regulations, would enter the food chain in NI and then move through the wider EU single market.

He said while there "legitimate concerns" from the EU, it was not an "unresolvable problem" given the heavy regulation of the sector.

Meanwhile, the British Veterinary Association (BVA) NI branch president Esther Skelly-Smith told the Lords if the grace period expires without a deal, the potential consequences are "vast and severe".

"Northern Ireland would be left facing a very real public health emergency and serious implications for the farming industry as well as potentially devastating outcomes for the equine sector and companion animals unable to get the treatment they need," she said.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!